BridgeMD
L-carnitine as an adjunct treatment for septic shock patients with acute kidney injury: a multicentre, randomized, 2-parallel group, superiority trial
EU CTIS ID: 2024-512508-21-00
What this study is testing
The primary objective of this study is to compare 28 day mortality rates between septic shock patients with acute renal insufficiency treated via L-Carnitine (as an adjunct therapy) versus a similar group of patients not receiving L-Carnitine adjunct therapy.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • The emergency inclusion procedure was correctly applied according to French law (signature of consent form by a patient-designated trusted person or a family member, or a medical decision to proceed with patient inclusion if the latter two persons are unavailable) ---- OR ---- signature of the consent form by the patient
- • The patient must be insured or beneficiary of a health insurance plan
- • The patient is at least 18 years old
- • The patient was admitted to an intensive care unit (participating in the study) for sepsis or septic shock and presented with acute renal failure requiring, at some point, the use of extra-renal purification
- The patient has sepsis or septic shock according to international criteria SEPSIS 3 (Singer et al, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) ; JAMA. 2016)
- • The patient has acute renal insufficiency with an KDIGO score of 3
You likely can't join if
- • The patient is participating in, or has participated in over the past three months, another interventional study that may interfere with the results or conclusions of this study
- • Septic shock without associated AKI
- • Patients with a known allergy to L-Carnitine or other component of levocarnil oral solution or for injection
- • Pre-existing chronic disease requiring dialysis
- • The patient has stage 4 CKD with baseline DFG (CDK) if known <30 ml
- • History of seizures or epilepsy
See the full eligibility criteria
- • The emergency inclusion procedure was correctly applied according to French law (signature of consent form by a patient-designated trusted person or a family member, or a medical decision to proceed with patient inclusion if the latter two persons are unavailable) ---- OR ---- signature of the consent form by the patient
- • The patient must be insured or beneficiary of a health insurance plan
- • The patient is at least 18 years old
- • The patient was admitted to an intensive care unit (participating in the study) for sepsis or septic shock and presented with acute renal failure requiring, at some point, the use of extra-renal purification
- The patient has sepsis or septic shock according to international criteria SEPSIS 3 (Singer et al, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) ; JAMA. 2016)
- • The patient has acute renal insufficiency with an KDIGO score of 3
- • The patient has started continuous renal replacement therapy (CRRT) or intermittent renal replacement therapy (IRRT) within the past 72 hours, or will start RRT (CRRT or IRRT) within the next 72 hours.
- • The patient is participating in, or has participated in over the past three months, another interventional study that may interfere with the results or conclusions of this study
- • Septic shock without associated AKI
- • Patients with a known allergy to L-Carnitine or other component of levocarnil oral solution or for injection
- • Pre-existing chronic disease requiring dialysis
- • The patient has stage 4 CKD with baseline DFG (CDK) if known <30 ml
- • History of seizures or epilepsy
- • Chronic bowel disease or history of chronic diarrhoea
- • Under treatment with sodium valproate
- • The patient is in an exclusion period determined by a previous study
- • The patient is under judicial protection, or is an adult under guardianship
- • The patient is pregnant, parturient or breastfeeding
- • The patient is susceptible to procreate and does not use methods of effective contraception (contraceptive hormonal ring, surgical contraception, contraceptive implant, contraceptive pill, male or female sheaths, skin patch, intrauterine contraceptive device)
- • If the patient is unable to sign a consent form: the patient-designated trusted person or family member refuses to sign the consent form
- • If the patient is unable to sign a consent form: It is impossible to correctly inform the patient-designated trusted person or family member
- • The patient is able/apt to sign a consent form, but refuses to do so
- • The patient is able/apt to sign a consent form, but cannot be correctly informed
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.